CN115671408A - Substance capable of avoiding granulation tissue hyperplasia - Google Patents
Substance capable of avoiding granulation tissue hyperplasia Download PDFInfo
- Publication number
- CN115671408A CN115671408A CN202211340164.XA CN202211340164A CN115671408A CN 115671408 A CN115671408 A CN 115671408A CN 202211340164 A CN202211340164 A CN 202211340164A CN 115671408 A CN115671408 A CN 115671408A
- Authority
- CN
- China
- Prior art keywords
- copolymer
- pouring
- solution
- hours
- reaction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010063560 Excessive granulation tissue Diseases 0.000 title claims abstract description 11
- 210000001126 granulation tissue Anatomy 0.000 title claims abstract description 11
- 239000000126 substance Substances 0.000 title claims abstract description 11
- 206010020718 hyperplasia Diseases 0.000 title abstract description 7
- 229920001577 copolymer Polymers 0.000 claims abstract description 33
- 238000005507 spraying Methods 0.000 claims abstract description 14
- 238000000034 method Methods 0.000 claims abstract description 12
- 239000003814 drug Substances 0.000 claims abstract description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 42
- 238000006243 chemical reaction Methods 0.000 claims description 34
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 27
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 24
- 239000007788 liquid Substances 0.000 claims description 24
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 18
- 238000001035 drying Methods 0.000 claims description 17
- 238000003756 stirring Methods 0.000 claims description 16
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 12
- 239000003054 catalyst Substances 0.000 claims description 12
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 12
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 9
- -1 benzyl bromoacetyl aspartate Chemical compound 0.000 claims description 9
- 239000001110 calcium chloride Substances 0.000 claims description 9
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 9
- 239000003208 petroleum Substances 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 7
- 230000035755 proliferation Effects 0.000 claims description 7
- 239000007787 solid Substances 0.000 claims description 7
- JJTUDXZGHPGLLC-IMJSIDKUSA-N 4511-42-6 Chemical compound C[C@@H]1OC(=O)[C@H](C)OC1=O JJTUDXZGHPGLLC-IMJSIDKUSA-N 0.000 claims description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 6
- 229920000669 heparin Polymers 0.000 claims description 6
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 claims description 6
- 229960001008 heparin sodium Drugs 0.000 claims description 6
- 229910052757 nitrogen Inorganic materials 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 3
- 229940009098 aspartate Drugs 0.000 claims description 3
- 230000015572 biosynthetic process Effects 0.000 claims description 3
- 238000005119 centrifugation Methods 0.000 claims description 3
- 238000005238 degreasing Methods 0.000 claims description 3
- 238000004821 distillation Methods 0.000 claims description 3
- 238000011049 filling Methods 0.000 claims description 3
- 238000005984 hydrogenation reaction Methods 0.000 claims description 3
- 239000005457 ice water Substances 0.000 claims description 3
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 claims description 3
- 229920000642 polymer Polymers 0.000 claims description 3
- 238000006116 polymerization reaction Methods 0.000 claims description 3
- 239000002244 precipitate Substances 0.000 claims description 3
- 230000001376 precipitating effect Effects 0.000 claims description 3
- 239000003755 preservative agent Substances 0.000 claims description 3
- 230000002335 preservative effect Effects 0.000 claims description 3
- 238000007789 sealing Methods 0.000 claims description 3
- 238000003786 synthesis reaction Methods 0.000 claims description 3
- KSBAEPSJVUENNK-UHFFFAOYSA-L tin(ii) 2-ethylhexanoate Chemical compound [Sn+2].CCCCC(CC)C([O-])=O.CCCCC(CC)C([O-])=O KSBAEPSJVUENNK-UHFFFAOYSA-L 0.000 claims description 3
- NZHGWWWHIYHZNX-CSKARUKUSA-N tranilast Chemical group C1=C(OC)C(OC)=CC=C1\C=C\C(=O)NC1=CC=CC=C1C(O)=O NZHGWWWHIYHZNX-CSKARUKUSA-N 0.000 claims description 3
- 229960005342 tranilast Drugs 0.000 claims description 3
- 238000001291 vacuum drying Methods 0.000 claims description 3
- 239000002699 waste material Substances 0.000 claims description 3
- 239000007921 spray Substances 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 1
- 238000002513 implantation Methods 0.000 abstract description 6
- 238000005469 granulation Methods 0.000 abstract description 3
- 230000003179 granulation Effects 0.000 abstract description 3
- 210000003437 trachea Anatomy 0.000 abstract description 3
- 230000000694 effects Effects 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 3
- 208000031481 Pathologic Constriction Diseases 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 208000037804 stenosis Diseases 0.000 description 2
- 230000036262 stenosis Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 206010003598 Atelectasis Diseases 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 208000007123 Pulmonary Atelectasis Diseases 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- 239000000560 biocompatible material Substances 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 201000004193 respiratory failure Diseases 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a substance capable of avoiding granulation tissue hyperplasia, which comprises spraying medicine and copolymer with the weight ratio of 3:1, wherein the spraying is carried out by a spraying device, and the speed in the spraying process is 1 ml/min. The invention can effectively inhibit granulation hyperplasia, has strong practicability and functionality, and can be widely applied to the technical field of trachea valve and stent implantation.
Description
Technical Field
The invention relates to the technical field of trachea valve and stent implantation, in particular to a substance capable of avoiding granulation tissue hyperplasia.
Background
The stenosis of the trachea and the bronchus caused by various reasons can cause various clinical symptoms such as obstructive pulmonary inflammation, atelectasis, dyspnea and the like, and serious patients can have respiratory failure and are life threatening. Surgical treatment is usually adopted for the patients in the past, and the treatment is difficult, the wound is large, and the risk is high. In recent years, with the development of endoscope technology, biocompatible materials and stent fabrication technology, the airway flap and stent implantation technology is mature and attracts more and more attention. Through valve and bracket implantation, most patients with narrow air passages and slow obstruction of the lung can benefit, and symptoms can be quickly relieved. Therefore, valve and stent implantation become one of the important means for treating airway stenosis and chronic obstructive pulmonary disease.
However, the implantation of the valve and the stent in the air passage has the problem of stimulating granulation tissue proliferation to cause the restenosis of the tube cavity, which is a great problem influencing the clinical curative effect after the valve and the stent are implanted. Therefore, a technique capable of solving this problem is yet to be proposed.
Disclosure of Invention
In order to solve the problems, the invention provides a medicament capable of effectively preventing the granulation hyperplasia.
The technical scheme provided by the invention is as follows:
a substance capable of preventing granulation tissue proliferation comprises a spray coating agent and a copolymer in a weight ratio of 3:1, which is sprayed by a spray coating device at a speed of 1 ml/min during the spraying process.
Preferably, the copolymer comprises the following preparation steps:
1) Synthesis of benzyl bromoacetyl aspartate:
taking a 500ml flask, connecting nitrogen by a tee joint, vacuumizing, and filling nitrogen for three times;
dripping 4ml of NaoH into the bottle at constant pressure;
controlling the number of drops, and measuring the number to be 8-9 by using a PH test paper;
the reaction process is carried out in a stirrer, and the whole process is controlled within 30-40 minutes;
adding 35ml of concentrated hydrochloric acid, and adjusting the pH value to 2.0;
adding 100ml of saturated saline, fully shaking up, pouring the lower waste liquid, and adding 100ml of saturated saline for five times;
distilling to obtain lower layer liquid;
2) Catalyst preparation:
adding 100ml of dichloromethane and 10g of calcium chloride into a distillation flask;
adding stannous octoate;
putting into a drying box;
extracting the two liquids by using a syringe, adding the two liquids in a certain amount, shaking the two liquids uniformly, and adding the mixture to 50ml to obtain 10g of dichloromethane to calcium chloride, wherein the ratio of the dichloromethane to the calcium chloride is 100ml;
3) Polymerization to give a copolymer:
2g of morpholine dione benzyl ester, 10g of L-lactide, 1.5ml of catalyst, reaction temperature of 150-155 ℃ and 6 hours;
putting the L-lactide in a drying box, and vacuumizing the drying box;
pouring 20g L-propyl lactide into a reaction bottle;
4g of morpholine dione benzyl ester is added into a reaction bottle;
adding the prepared catalyst solution, and sealing the reaction bottle;
fixing the reaction bottle in a 155-DEG oil bath pot and stirring for 6 hours;
crushing the reaction bottle, and taking out the solid;
putting the solid into a 600ml measuring cup, adding 300ml of dichloromethane, and stirring on a stirrer until the dichloromethane is completely dissolved;
filtering with a second filter;
adding a stirrer into a 1000ml beaker, and slowly adding 800ml of methanol into the filtered liquid to obtain a cotton-like substance;
using toilet paper to suck the methanol;
putting the plate filled with the copolymer into a 50-DEG vacuum drying oven by using a preservative film to dry for 4-12 hours;
putting the dried copolymer in a dryer for later use;
4) Degreasing protection of the copolymer:
10g of the copolymer was placed in a 1000ml spherical reaction flask;
adding 400ml of tetrahydrofuran, and stirring until the tetrahydrofuran is dissolved;
adding 3.5g of palladium-carbon hydrogenation catalyst and fully shaking 100ml of anhydrous methanol;
pouring the solution after shaking into tetrahydrofuran solution;
after reacting for 3 hours, pouring the solution into a No. 4 filter for filtering;
pouring the liquid into a centrifuge tube for centrifugation, carrying out 13000 revolutions for 10 minutes;
pouring the centrifuged liquid into petroleum ether to obtain a polymer;
drying in a drying oven for 6 hours in vacuum;
5) Heparinizing:
dissolving 1.6g heparin sodium in 53ml water and 0.1m HCL 10ml water;
slowly pouring the dissolved heparin sodium solution into a reaction bottle and stirring;
placing the reaction bottle in ice water with the temperature of 4 ℃ and stirring for reaction for 24 hours;
pouring petroleum ether into a 600ml beaker, adding a stirrer, and slowly adding the solution to precipitate to obtain a precipitate;
dissolving the copolymer in tetrahydrofuran;
centrifuging for 10 minutes by using a centrifuge;
precipitating the solution in petroleum ether to obtain a copolymer;
the copolymer was dried at room temperature for 24 hours.
Preferably, the spraying medicine is tranilast with the specification of 50-200mg/kg.
Compared with the prior art, the invention has the advantages that:
by adopting the technical scheme provided by the invention, the effect of effectively preventing the granulation hyperplasia is achieved, and the curative effect is good
Detailed Description
The present invention will be described in further detail with reference to examples.
A substance capable of preventing granulation tissue proliferation comprises a spray coating agent and a copolymer in a weight ratio of 3:1, which is sprayed by a spray coating device at a speed of 1 ml/min during the spraying process.
The copolymer comprises the following preparation steps:
1) Synthesis of benzyl bromoacetyl aspartate:
taking a 500ml flask, connecting nitrogen by a tee joint, vacuumizing, and filling nitrogen for three times;
dripping 4ml of NaoH into the bottle at constant pressure;
controlling the number of drops, and measuring the number to be 8-9 by using a PH test paper;
the reaction process is carried out in a stirrer, and the whole process is controlled within 30-40 minutes;
adding 35ml of concentrated hydrochloric acid, and adjusting the pH value to 2.0;
adding 100ml of saturated saline, fully shaking up, pouring the lower waste liquid, and adding 100ml of saturated saline for five times;
distilling to obtain lower layer liquid;
2) Catalyst preparation:
adding 100ml of dichloromethane and 10g of calcium chloride into a distillation flask;
adding stannous octoate;
putting the mixture into a drying box;
extracting the two liquids by using a syringe, adding the two liquids in a certain amount, shaking the two liquids uniformly, and adding the mixture to 50ml to obtain 10g of dichloromethane to calcium chloride, wherein the ratio of the dichloromethane to the calcium chloride is 100ml;
3) Polymerization to give a copolymer:
2g of morpholine dione benzyl ester, 10g of L-lactide, 1.5ml of catalyst, reaction temperature of 150-155 ℃ and 6 hours;
putting the L-lactide in a drying box, and vacuumizing the drying box;
pouring 20g L-propyl lactide into a reaction bottle;
4g of morpholine dione benzyl ester is added into a reaction bottle;
adding the prepared catalyst solution, and sealing the reaction bottle;
fixing the reaction bottle in a 155-DEG oil bath pot and stirring for 6 hours;
crushing the reaction bottle, and taking out the solid;
putting the solid into a 600ml measuring cup, adding 300ml of dichloromethane, and stirring on a stirrer until the solid is completely dissolved;
filtering with a second filter;
adding a stirrer into a 1000ml beaker, and slowly adding 800ml of methanol into the filtered liquid to obtain a cotton-like substance;
using toilet paper to suck the methanol;
putting the plate filled with the copolymer into a 50-DEG vacuum drying oven by using a preservative film to dry for 4-12 hours;
putting the dried copolymer in a dryer for standby;
4) Degreasing protection of the copolymer:
10g of the copolymer was placed in a 1000ml spherical reaction flask;
adding 400ml of tetrahydrofuran, and stirring until the tetrahydrofuran is dissolved;
adding 3.5g of palladium-carbon hydrogenation catalyst and 100ml of anhydrous methanol, and fully shaking up;
pouring the uniformly shaken solution into a tetrahydrofuran solution;
after reacting for 3 hours, pouring the solution into a No. 4 filter for filtering;
pouring the liquid into a centrifuge tube for centrifugation, carrying out 13000 revolutions for 10 minutes;
pouring the centrifuged liquid into petroleum ether to obtain a polymer;
drying in a drying oven for 6 hr;
5) Heparinizing:
dissolving 1.6g heparin sodium in 53ml of water and 10ml of 0.1m HCL;
slowly pouring the dissolved heparin sodium solution into a reaction bottle and stirring;
placing the reaction bottle in ice water with the temperature of 4 ℃ and stirring for reaction for 24 hours;
pouring petroleum ether into a 600ml beaker, adding a stirrer, and slowly adding the solution to precipitate to obtain a precipitate;
dissolving the copolymer in tetrahydrofuran;
centrifuging for 10 minutes by using a centrifuge;
precipitating the solution in petroleum ether to obtain a copolymer;
the copolymer was dried at room temperature for 24 hours.
The spray coating medicine is tranilast with a specification of 50-200mg/kg.
In the implementation process of the technical scheme provided by the invention, the effect of avoiding granulation tissue proliferation can be achieved, and the operability is strong.
Moreover, the invention is applied to the specific clinical experiment process, achieves more obvious technical effect, simplifies the medical operation of medical care personnel in the implementation process, and has accurate operation.
Other adjustments to the stirring process, the reaction temperature during the preparation of the copolymer, and the time of drying the copolymer plate in the drying oven as set forth in the present invention are within the scope of the present application.
Claims (3)
1. A substance capable of preventing granulation tissue proliferation, comprising a spray drug and a copolymer in a weight ratio of 3:1, which is sprayed by a spray device at a speed of 1 ml/min during spraying.
2. The substance capable of avoiding the proliferation of granulation tissue as claimed in claim 1, wherein said copolymer comprises the following preparation steps:
1) Synthesis of benzyl bromoacetyl aspartate:
taking a 500ml flask, connecting nitrogen by a tee joint, vacuumizing, and filling nitrogen for three times;
dripping 4ml of NaoH into the bottle at constant pressure;
controlling the number of drops, and measuring the number to be 8-9 by using a PH test paper;
the reaction process is carried out in a stirrer, and the whole process is controlled to be 30-40 minutes;
adding 35ml of concentrated hydrochloric acid, and adjusting the pH value to 2.0;
adding 100ml of saturated saline, fully shaking up, pouring the lower waste liquid, and adding 100ml of saturated saline for five times;
distilling to obtain lower layer liquid;
2) Catalyst preparation:
adding 100ml of dichloromethane and 10g of calcium chloride into a distillation flask;
adding stannous octoate;
putting the mixture into a drying box;
extracting the two liquids by using a syringe, adding the two liquids in a certain amount, shaking the two liquids uniformly, and adding the mixture to 50ml to obtain 10g of dichloromethane to calcium chloride, wherein the ratio of the dichloromethane to the calcium chloride is 100ml;
3) Polymerization to give a copolymer:
2g of morpholine dione benzyl ester, 10g of L-lactide, 1.5ml of catalyst, reaction temperature of 150-155 ℃ and 6 hours;
putting the L-lactide in a drying box, and vacuumizing the drying box;
pouring 20g L-propyl lactide into a reaction bottle;
4g of morpholine dione benzyl ester is added into a reaction bottle;
adding the prepared catalyst solution, and sealing the reaction bottle;
fixing the reaction bottle in a 155-DEG oil bath pot and stirring for 6 hours;
crushing the reaction bottle, and taking out the solid;
putting the solid into a 600ml measuring cup, adding 300ml of dichloromethane, and stirring on a stirrer until the dichloromethane is completely dissolved;
filtering with a second filter;
adding a stirrer into a 1000ml beaker, and slowly adding 800ml of methanol into the filtered liquid to obtain a cotton-like substance;
using toilet paper to suck the methanol;
putting the plate filled with the copolymer into a 50-DEG vacuum drying oven by using a preservative film to dry for 4-12 hours;
putting the dried copolymer in a dryer for later use;
4) Degreasing protection of the copolymer:
10g of the copolymer was placed in a 1000ml spherical reaction flask;
adding 400ml of tetrahydrofuran, and stirring until the tetrahydrofuran is dissolved;
adding 3.5g of palladium-carbon hydrogenation catalyst and 100ml of anhydrous methanol, and fully shaking up;
pouring the solution after shaking into tetrahydrofuran solution;
after reacting for 3 hours, pouring the solution into a No. 4 filter for filtering;
pouring the liquid into a centrifuge tube for centrifugation, carrying out 13000 revolutions for 10 minutes;
pouring the centrifuged liquid into petroleum ether to obtain a polymer;
drying in a drying oven for 6 hr;
5) Heparinizing:
dissolving 1.6g heparin sodium in 53ml water and 0.1m HCL 10ml water;
slowly pouring the dissolved heparin sodium solution into a reaction bottle and stirring;
placing the reaction bottle in ice water with the temperature of 4 ℃ and stirring for reaction for 24 hours;
pouring petroleum ether into a 600ml beaker, adding a stirrer, and slowly adding the solution to precipitate to obtain a precipitate;
dissolving the copolymer in tetrahydrofuran;
centrifuging for 10 minutes by using a centrifuge;
precipitating the solution in petroleum ether to obtain a copolymer;
the copolymer was dried at room temperature for 24 hours.
3. The dosing method capable of preventing granulation tissue proliferation as claimed in claim 2, wherein the spraying medicine is tranilast with a specification of 50-200mg/kg.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211340164.XA CN115671408A (en) | 2022-10-29 | 2022-10-29 | Substance capable of avoiding granulation tissue hyperplasia |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211340164.XA CN115671408A (en) | 2022-10-29 | 2022-10-29 | Substance capable of avoiding granulation tissue hyperplasia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115671408A true CN115671408A (en) | 2023-02-03 |
Family
ID=85046759
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211340164.XA Pending CN115671408A (en) | 2022-10-29 | 2022-10-29 | Substance capable of avoiding granulation tissue hyperplasia |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115671408A (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1418641A (en) * | 2001-11-12 | 2003-05-21 | 华东理工大学 | Polyester with its main train having amino acid and contg. active drug, and its prepn. method |
| US20030108588A1 (en) * | 2001-09-17 | 2003-06-12 | Jianbing Chen | Stent coated with a sustained-release drug delivery and method for use thereof |
| AU2004325203A1 (en) * | 2004-11-24 | 2006-06-01 | Seo Hong Yoo | Dried forms of aqueous solubilized bile acid dosage formulation: preparation and uses thereof |
| CN101181650A (en) * | 2006-08-02 | 2008-05-21 | 上海市普陀区中心医院 | Bracket for controlling releasing and elution of tranilast medicament coating |
| US20100074934A1 (en) * | 2006-12-13 | 2010-03-25 | Hunter William L | Medical implants with a combination of compounds |
-
2022
- 2022-10-29 CN CN202211340164.XA patent/CN115671408A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030108588A1 (en) * | 2001-09-17 | 2003-06-12 | Jianbing Chen | Stent coated with a sustained-release drug delivery and method for use thereof |
| CN1418641A (en) * | 2001-11-12 | 2003-05-21 | 华东理工大学 | Polyester with its main train having amino acid and contg. active drug, and its prepn. method |
| AU2004325203A1 (en) * | 2004-11-24 | 2006-06-01 | Seo Hong Yoo | Dried forms of aqueous solubilized bile acid dosage formulation: preparation and uses thereof |
| CN101181650A (en) * | 2006-08-02 | 2008-05-21 | 上海市普陀区中心医院 | Bracket for controlling releasing and elution of tranilast medicament coating |
| US20100074934A1 (en) * | 2006-12-13 | 2010-03-25 | Hunter William L | Medical implants with a combination of compounds |
Non-Patent Citations (2)
| Title |
|---|
| 张晓飞: "《吗啉-2, 5-二酮衍生物的合成及其与丙交酯的共聚研究》", 《中国优秀硕士学位论文全文数据库 工程科技Ⅰ辑》, no. 10, pages 014 - 122 * |
| 赵燕超等: "《肝素化吗林二酮衍生物与L-丙交酯共聚物制备与表征》", 《2005年全国高分子学术论文报告会》, pages 638 - 125 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100293043B1 (en) | Photocurable glycosaminoglycan derivatives, cross-linked glycosaminoglycans and methods for preparing the same | |
| ES2459743T3 (en) | Sustained release preparation for tissue regeneration therapy | |
| KR20030078797A (en) | Compositions and medical devices utilizing bioabsorbable liquid polymers | |
| WO2021208688A1 (en) | Method for preparing anti-intestinal adhesion double-layer biological gel and double-layer biological gel | |
| AU2014210266B2 (en) | Positioning, quick-release bioadhesion agent and use | |
| JP2004507586A (en) | Percarboxylic esterified polysaccharides and methods for producing them | |
| MX2010007282A (en) | Mucosal tissue dressing and method of use. | |
| RU2567049C2 (en) | Application of nitrocarboxylic acids for treatment, diagnostics and prevention of aggressive forms of healing | |
| JP2017528527A (en) | Injectable microparticles for superlocalized release of therapeutic agents | |
| CN115227639B (en) | A temperature-sensitive modified chitin hydrogel-loaded local anesthetic sustained-release analgesic system, preparation method and application thereof | |
| CN110464874B (en) | A kind of polymer material with nerve tissue repairing activity and its preparation method and application | |
| WO2000053194A1 (en) | Remedies for joint diseases | |
| CN116251079A (en) | Effervescent soluble microneedle patch for platelet-rich plasma and preparation method thereof | |
| CN115671408A (en) | Substance capable of avoiding granulation tissue hyperplasia | |
| CN115707489A (en) | Medicine adding method capable of preventing granulation tissue proliferation | |
| CN115671409A (en) | Medicine adding method and medicine capable of preventing granulation tissue proliferation | |
| CA3035659C (en) | Sulfated glycosaminoglycan biomaterials as proteoglycan mimics | |
| WO2002009787A1 (en) | Microparticulate biomaterial composition for medical use | |
| US20030211166A1 (en) | Microparticulate biomaterial composition for medical use | |
| CN107865868B (en) | New application of amlexanox | |
| CN116236457B (en) | A bone-targeted oral micro-nano hydrogel microsphere and its preparation method and application | |
| CN115382026B (en) | Medicine-containing coating material and preparation thereof, medicine-containing coating medical instrument and preparation thereof | |
| CN108969797A (en) | A kind of load lipidosome gel and preparation method thereof with electro photoluminescence and the neural scar effect of inhibition | |
| CN113116863B (en) | Percutaneous absorption patch and application and preparation method thereof | |
| CN111378125B (en) | PEBP block polymer gel and its preparation and application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20230203 |
|
| RJ01 | Rejection of invention patent application after publication |